Financial Performance - The company's revenue for Q1 2025 reached ¥742,251,316.24, representing a year-on-year increase of 9.82% compared to ¥675,882,973.16 in the same period last year[5] - Net profit attributable to shareholders was ¥27,279,356.63, marking a significant increase of 61.18% from ¥16,924,936.43 in the previous year[5] - Basic and diluted earnings per share rose to ¥0.18, reflecting a growth of 63.64% compared to ¥0.11 in the same quarter last year[5] - Net profit for the current period was ¥28,776,862.83, representing a 51.5% increase from ¥19,042,640.10 in the previous period[20] - Earnings per share (EPS) for the current period was ¥0.18, compared to ¥0.11 in the previous period, indicating a 63.6% increase[21] Cash Flow - The net cash flow from operating activities increased by 54.87% to ¥194,676,885.40, up from ¥125,706,825.28 in Q1 2024[5] - Cash inflow from operating activities totaled ¥755,768,471.98, up from ¥679,993,838.41, marking an increase of 11.1%[23] - The net cash flow from operating activities was 125.71 million in the previous period, reflecting a growth of 55%[24] - The net cash flow from investing activities improved by 33.81%, decreasing to -¥129,970,029.96 from -¥196,363,723.78 in the previous year[8] - The company reported a net cash outflow from investing activities of 196.36 million previously[24] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥4,697,051,407.54, a 2.15% increase from ¥4,598,026,724.34 at the end of the previous year[5] - Current assets increased to CNY 1,042,289,047.66 from CNY 869,259,065.91, representing a growth of about 19.93%[15] - Total liabilities rose to ¥2,539,477,942.20, compared to ¥2,476,861,122.42, an increase of 2.5%[18] - Total equity attributable to shareholders reached ¥2,134,699,722.16, up from ¥2,101,497,552.89, a growth of 1.6%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,024[10] - The largest shareholder, Chengdu Puri Century Investment Co., Ltd., holds a 35.91% stake, amounting to 53,729,585 shares, with 20,541,200 shares pledged[10] - The company reported a total of 3,603,810 shares held by Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, making it one of the top shareholders[12] - The company has a total of 1,900,073 shares held by Industrial and Commercial Bank of China - Rongtong Health Industry Flexible Allocation Mixed Securities Investment Fund, indicating significant institutional interest[12] Operating Costs and Expenses - Total operating costs amounted to ¥690,187,707.10, up from ¥636,079,700.34, reflecting a rise of 8.5%[19] - Research and development expenses were ¥2,461,386.01, slightly up from ¥2,410,662.58, indicating a focus on innovation[20] - The company reported a decrease in tax expenses to ¥23,086,518.32 from ¥17,934,906.28, a reduction of 28.5%[20] - Cash outflows for employee compensation were 237.42 million, representing an increase of 13.8%[24] Investment Activities - Total cash outflow from investing activities amounted to 196.39 million previously, indicating a significant increase in investment spending[24] - The cash inflow from investment activities was 25.50 million in the previous period, marking a substantial increase[24]
普瑞眼科(301239) - 2025 Q1 - 季度财报